GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Retained Earnings

TOT Biopharm International Co (HKSE:01875) Retained Earnings : HK$-1,778 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. TOT Biopharm International Co's retained earnings for the quarter that ended in Jun. 2024 was HK$-1,778 Mil.

TOT Biopharm International Co's quarterly retained earnings declined from Jun. 2023 (HK$-1,816 Mil) to Dec. 2023 (HK$-1,841 Mil) but then increased from Dec. 2023 (HK$-1,841 Mil) to Jun. 2024 (HK$-1,778 Mil).

TOT Biopharm International Co's annual retained earnings increased from Dec. 2021 (HK$-1,954 Mil) to Dec. 2022 (HK$-1,838 Mil) but then declined from Dec. 2022 (HK$-1,838 Mil) to Dec. 2023 (HK$-1,841 Mil).


TOT Biopharm International Co Retained Earnings Historical Data

The historical data trend for TOT Biopharm International Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOT Biopharm International Co Retained Earnings Chart

TOT Biopharm International Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial -1,171.82 -1,590.36 -1,953.78 -1,837.59 -1,841.14

TOT Biopharm International Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,888.81 -1,837.59 -1,816.43 -1,841.14 -1,778.16

TOT Biopharm International Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


TOT Biopharm International Co  (HKSE:01875) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


TOT Biopharm International Co Business Description

Traded in Other Exchanges
N/A
Address
120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.
Executives
Center Laboratories, Inc. 2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited 2301 Trustee
Chengwei Evergreen Capital, Lp 2101 Beneficial owner
Center Laboratories Inc. 2101 Beneficial owner
Chengwei Evergreen Management, Llc 2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited 2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines